Winton Group’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-8,264
Closed -$392K 743
2023
Q4
$392K Buy
8,264
+11
+0.1% +$462 0.03% 438
2023
Q3
$366K Buy
+8,253
New +$383K 0.03% 469
2022
Q1
Sell
-8,100
Closed -$374K 1059
2021
Q4
$374K Sell
8,100
-25,847
-76% -$1.04M 0.02% 764
2021
Q3
$1.14M Buy
33,947
+5,640
+20% +$192K 0.06% 436
2021
Q2
$833K Sell
28,307
-5,208
-16% -$144K 0.04% 634
2021
Q1
$864K Buy
33,515
+2,854
+9% +$68.2K 0.05% 550
2020
Q4
$699K Sell
30,661
-21,117
-41% -$488K 0.05% 607
2020
Q3
$1.11M Sell
51,778
-12,760
-20% -$287K 0.04% 781
2020
Q2
$1.5M Buy
64,538
+40,354
+167% +$866K 0.04% 788
2020
Q1
$516K Sell
24,184
-3,117
-11% -$74.2K 0.01% 1018
2019
Q4
$638K Buy
+27,301
New +$638K 0.01% 1176

Other funds holding IRMD

Winton Group's IRMD Position: Q1 2024 in Review

Winton Group sold out of iRadimed (IRMD) in Q1 2024, closing a stake of 8,264 shares — an estimated $392K sold.

Winton Group first reported a position in IRMD in Q4 2019 and held it in 11 quarters. The position peaked at $1.5M in Q2 2020. 126 funds tracked by Wall St. Rank hold IRMD as of Q1 2024.

  • Winton Group reported no remaining iRadimed position as of Q1 2024 after selling out during the quarter.
  • Winton Group sold 8,264 iRadimed shares in Q1 2024, an estimated $392K.
  • Winton Group first reported a position in iRadimed in Q4 2019 and held it in 11 quarters.
  • Winton Group's iRadimed position peaked at $1.5M in Q2 2020.
  • 126 funds tracked by Wall St. Rank held iRadimed as of Q1 2024.

Based on Winton Group's 13F filing for Q1 2024, filed 14 May 2024.